Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas

Tony C.Y. Chuang, Alice Y.C. Chuang, Luana Poeta, Wayne M. Koch, Joseph A. Califano, Ralph P. Tufano

Research output: Contribution to journalArticlepeer-review

34 Scopus citations


Background. An activating point mutation of the BRAF oncogene results in a V600E amino acid missense mutation found in a majority of papillary thyroid carcinomas (PTC). Methods. In this study, 28 matched tumor and serum samples obtained from patients with both benign and malignant thyroid disorders were analyzed for BRAF mutation using a gap-ligase chain reaction technique. Results. The BRAF mutation was absent in tumor DNA samples obtained from patients with benign adenomas, follicular neoplasms or carcinoma, and thyroid lymphoma. In contrast, 5 of 14 PTC tumors were positive for the BRAF mutation. Moreover, 3 of 14 patients with PTC were positive for BRAF mutation in serum and tumor. Of these 3 patients, 2 had lymph node metastasis and 2 had PTC in background of the Hashimoto's thyroiditis. Conclusions. The detection of free circulating mutant BRAF in patients with PTC is possible and future studies are warranted to determine its clinical significance.

Original languageEnglish (US)
Pages (from-to)229-234
Number of pages6
JournalHead and Neck
Issue number2
StatePublished - Feb 2010


  • BRAF
  • Biomarker
  • Serum DNA
  • Thyroid carcinoma

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Detectable BRAF mutation in serum DNA samples from patients with papillary thyroid carcinomas'. Together they form a unique fingerprint.

Cite this